Verisante Technology, Inc. Retains Hamza Thindal Capital Corp. for Investor Relations

Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology, announced
today that it has retained Hamza Thindal Capital Corp. (the "Firm" or "Hamza
Thindal") for investor relations to help broaden investor awareness via the
Firm's established network of investors in North America, Europe and the
Gulf/MENA Region.


"We are very pleased to start working with the team at Verisante as they enter
an exciting phase of their commercialization strategy. As a medical doctor I
understand the real need for the revolutionary products in Verisante's
pipeline," said Dr. Essam Hamza MD, CEO of Hamza Thindal. "Our unique approach,
experience and successful track record of working with development stage Health
Care companies fits very well with Verisante as the company begins full
commercialization," added Kam Thindal, President of Hamza Thindal. 


"Hamza Thindal's experience and expertise in the healthcare market is
impressive," said Thomas Braun, President & CEO of Verisante. "We are looking
forward to working with their team to increase awareness and strengthen
shareholder communication."


The agreement with Hamza Thindal is for a one-year term that may be terminated
by either party in writing with 3 months notice. The Company will pay a
consulting fee to Hamza Thindal of $7,500 per month plus approved expenses
incurred on behalf of the Company and has granted 300,000 share purchase options
at $0.75 per share. The options are exercisable for 24 months from the grant
date and are subject to vesting over 12 months with no more than 1/4 of the
options vesting in any three month period in accordance with TSX Venture Policy.
Both the consulting agreement and the options grant are subject to the approval
of the TSX Venture Exchange. Neither Hamza Thindal nor any of its principals
have an ownership interest, directly or indirectly, in Verisante or its
securities prior to this agreement.


About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative
systems for the early detection of cancer. The Verisante Aura(TM) for skin
cancer detection and the Verisante Core(TM) series for lung, colon and cervical
cancer detection utilize a proprietary cancer detection platform while the
operating software and probe technology are unique to each device. The cancer
detection platform was developed by the BC Cancer Agency and tested and refined
at the Skin Care Centre at Vancouver General Hospital. This exclusive platform
technology allows Verisante to develop and offer a range of compact,
non-invasive cancer detection devices that offer physicians immediate results
for many of the most common cancers. Aura(TM) has been approved for sale in
Canada, Europe and Australia. The Core(TM) has not yet been approved for sale. 


Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New
Award" for 2011, and awarded a 2013 Prism Award for Innovation in Photonics.
Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by
the Canadian Cancer Society. 


About Hamza Thindal Capital Corp.

Hamza Thindal Capital is a Vancouver-based boutique capital markets firm
providing fundraising, investor relations (IR) and advisory to emerging
small-cap companies. The firm has the unique ability to combine fundraising and
investor relations expertise with a market centric focus. The integration of
these services provides our clients with a long term partner as their business
grows. For more information please visit: www.htcapitalcorp.com.


Youtube:  www.youtube.com/verisante 

Twitter: www.twitter.com/verisante 

Facebook: www.facebook.com/verisante  

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to,
statements regarding the future commercialization of medical devices, the market
demand for these products and the proprietary protections the Company will
obtain with regard to the technology, all of which statements are subject to
market risks, and the possibility that the Company will not be able to obtain
patent protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ from those
projected due to a number of risks and uncertainties.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Verisante Technology, Inc.
Thomas Braun
President & CEO
[phone]
[e-mail]
www.verisante.com


Firm Contact Information:
Hamza Thindal Capital Corp.
[phone]
[e-mail]
www.htcapitalcorp.com